Financings in Brief: Oxis International

Oxis International: Raises $2,037,836 through private placement of 1,227,625 shares of common to Canadian and European investors. The Portland, Oregon diagnostics and drug developer will use the funds for R&D and marketing programs. The firm separately announced FDA marketing clearance of its Beta Lactamase Rapid Enzyme Detection Discs, which are used to "detect the production of the beta lactamase enzyme by certain antibiotic-resistant bacteria that cause infections." Marketing is expected to commence "as early as" the fourth quarter of 1995...